Status:
RECRUITING
Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
THOR Photomedicine Ltd
Conditions:
Myeloablative Allogeneic Hematopoietic Cell Transplantation
Intraoral Photobiomodulation Therapy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (all...
Detailed Description
As part of a transplant procedure patients will receive chemotherapy in a conditioning regimen in preparation of alloHCT as well as immunosuppressive medications to help prevent graft-versus-host dise...
Eligibility Criteria
Inclusion
- Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Tac-Mtx GVHD prophylaxis.
- Age ≥18 years.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion
- Participants who have had treatment with intraoral PBMT within four weeks of admission for HSCT.
- Participants who have a history of radiation therapy to the head and neck.
- Participants who have a history of photosensitivity or underlying disease with known photosensitivity.
- Participants who are planned to receive palifermin for OM prevention.
Key Trial Info
Start Date :
June 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 19 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05335434
Start Date
June 10 2022
End Date
July 19 2026
Last Update
December 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115